Dr. Swayampakula Ramakanth is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Ramakanth’s research covers companies operating in oncology, wound health, medical devices, spine health and animal health. Dr. Ramakanth possesses over ten years of experience as a Life Sciences Equity Analyst as well as seven years of biotechnology industry experience. Prior to joining H.C. Wainwright, Dr. Ramakanth worked as a Junior Analyst at both Jefferies and Merrill Lynch covering large cap pharmaceuticals.
Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Article - MediaH.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: Ekso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright
Article - MediaEkso’s Q4 pre-announcement ‘bodes well’ for 2020 growth, says H.C. Wainwright
TheFly, 10 January 2020
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $1.20 price target on Ekso Bionics, saying the pre-announced “record” fourth quarter “bodes well” for continued growth in 2020.
Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.
RELATED:
Article: H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy
Article - MediaH.C. Wainwright Starts Ekso Bionics (EKSO) at Buy
StreetInsider.com, 28 October 2019
H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on Ekso Bionics (NASDAQ: EKSO) with a Buy rating and a price target of $1.20.
Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.
RELATED:
